Novartis strikes $7.8 billion mRNA deal with China's Abogen
Swiss drug maker Novartis has signed a licensing and option agreement with Chinese biotech firm Abogen worth approximately $7.8 billion to advance RNA-based therapy.
Story updates
07:58:05 AM UTC
SquawkNews
Chinese biotech company Abogen said on Friday it signed a licensing deal worth about $7.8 billion with Swiss drug maker Novartis BX:NOT to advance RNA-based therapy.Novartis will gain exclusive rights to Abogen's experimental drug, ABO2203, and options to license other therapies based on Abogen's R…
8 billion with Swiss drug maker Novartis BX:NOT to advance RNA-based therapy.